eFFECTOR Therapeutics, Inc. is placing its bets on a breast cancer drug candidate following the failure in a mid-stage trial of tomivosertib for non-small cell lung cancer (NSCLC), an indication where some had forecast blockbuster sales. However, the company is not yet giving up on tomivosertib, which is also in early-stage development for acute myeloid leukemia (AML).
The biotech company announced 4 April that the Phase II KICKSTART trial combining tomivosertib with Merck & Co., Inc.’s...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?